Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice

Journal of Psychopharmacology

Volumn 31, Issue 12, 2017, Pages 1511-1518

  Nakata, Yusuke ^a   Kanahara, Nobuhisa ^b   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Antipsychotic; dopamine partial agonist; dopamine supersensitivity; schizophrenia; tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PALIPERIDONE; QUETIAPINE; VALPROIC ACID; ZIPRASIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

ADJUVANT THERAPY; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; HUMAN; LIMBIC SYSTEM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUPERSENSITIVITY; TARDIVE DYSKINESIA; TREATMENT-RESISTANT SCHIZOPHRENIA; UPREGULATION; CENTRAL NERVOUS SYSTEM SENSITIZATION; COMPLICATION; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM SENSITIZATION; DOPAMINE; DOPAMINE D2 RECEPTOR ANTAGONISTS; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 85034034138     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881117728428     Document Type: Review

References (74)

1. Azekawa T, Ohashi S, Itami A, (2011) Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr Dis Treat 7: 691–695.
2. Beaulieu JM, Gainetdinov RR, (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182–217.
3. Charron A, Hage CE, Servonnet A. (2015) 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur Neuropsychopharmacol 25: 2381–2393.
4. Chiliza B, Asmal L, Lilian S. (2015) Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Hum Psychopharmacol Clin Exp 30: 173–182.
5. Chouinard G, (1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5: 21–33.
6. Chouinard G, Annable L, Ross-Chouinard A, (1986) Supersensitivity psychosis and tardive dyskinesia: A survey in schizophrenic outpatients. Psychopharmacol Bull 22: 891–896.
7. Chouinard G, Chouinard VA, (2008) Atypical antipsychotics. CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77: 69–77.
8. Chouinard G, Jones BD, (1980) Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacological characteristics. Am J Psychiatry 137: 16–21.
9. Chouinard G, Jones BD, Annable L, (1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135: 1409–1410.
10. Chouinard G, Samaha AN, Chouinard VA. (2017) Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 86: 189–219.
11. Chouinard G, Sultan S, (1990) Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. Psychopharmacol Bull 26: 337–341.
12. Chouinard G, Vainer JL, Belanger MC. (1994) Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 18: 1129–1141.
13. Citrome L, (2006) A review of aripiprazole in the treatment of patients with schizophrenia or bipolar Ⅰdisorder. Neuropsychiatric Dis Treat 2: 427–443.
14. Davis KL, Rosenberg GS, (1979) Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 14: 699–703.
15. Fakra E, Azorin JM, (2012) Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother 13: 1923–1935.
16. Fallon P, Dursun SM, (2011) A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 25: 755–762.
17. Fallon P, Dursun S, Deakin B, (2012) Drug-induced supersensitivity psychosis revisited: Characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol 2: 13–22.
18. Gorwood P, (2006) Meeting everyday challenges: Antipsychotic therapy in the real world. Eur Neuropsychopharmacol 16(Suppl. 3): S156–S162.
19. Haddad PM, Das A, Keyhani S. (2012) Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: A systematic review of head-head comparisons. J Psychopharmacol 26(Suppl. 5): 15–26.
20. Hasan A, Falkai P, Wobrock T. (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13: 318–378.
21. Huang N, Ase AR, Hébert C. (1997) Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: Homogenate binding and autoradiographic studies. Neurochem Int 30: 277–290.
22. Inoue A, Miki S, Seto M. (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321: 105–111.
23. Inoue A, Osada K, Tagawa M. (2012) Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog Neuropsychopharmacol Biol Psychiatry 39: 156–162.
24. Iyo M, Tadokoro S, Kanahara N. (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33: 398–404.
25. Juarez-Reyes MG, Shumway M, Battle C. (1995) Eligibility for clozapine among public mental health clients. Psychiatr Serv 46: 801–806.
26. Kahn RS, Fleischhacker WW, Boster H. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizoaffective disorder: An open clinical trial. Lancet 371: 1085–1097.
27. Kane J, Honigfeld G, Singer J. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.
28. Kane JM, (1996) Factors which can make patients difficult to treat. Br J Psychiatry Suppl 31: 10–14.
29. Kane JM, Meltzer HY, Carson WH, Jr. (2007) Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 68: 213–223.
30. Kapur S, Zipursky R, Jones C. (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514–520.
31. Keefe RSE, Mohs RC, Losonczy MF. (1987) Characteristics of very poor outcome schizophrenia. Am J Psychiatry 144: 889–895.
32. Kho KH, Blansjaar BA, de Vries S. (2004) Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia. An open label study. Eur Arch Psychiatry Clin Neurosci 254: 371–379.
33. Kimura H, Kanahara N, Komatsu N. (2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 155: 52–58.
34. Kimura H, Kanahara N, Sasaki T. (2016) Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol 30: 795–802.
35. Köhler U, Schröder H, Augusatin W. (1994) A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci Lett 170: 99–102.
36. Lewis SW, Barnes TRE, Davies L. (2006) Randomized controlled trail of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32: 715–723.
37. Llorca PM, (2008) Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatr Res 161: 235–247.
38. Louzã MR, Bassitt DP, (2005) Maintenance treatment of severe tardive dyskinesia with clozapine. 5 years’ follow-up. J Clin Psychopharmacol 25: 180–182.
39. Mannaert E, Vermeulen A, Remmerie B. (2005) Pharmacokinetic profile of long-acting injectable risperidone at steady-state: Comparison with oral administration. L’Encéphale 31: 609–615.
40. Margolese HC, Chouinard G, Beauclair L, (2002) Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 22: 347–352.
41. Masand PS, Roca M, Turner MS. (2009) Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Primary Care Companion. J Clin Psychiatry 11: 147–154.
42. McEvoy JP, Lieberman JA, Stroup TS. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.
43. Mitchell AJ, Vancampfort D, Sweers K. (2013): Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—A systematic review and meta-analysis. Schizophr Bull 39: 306–318.
44. Molina JD, Jiménez-González AB, López-Muñoz F. (2012) Evolution of the concept of treatment-resistant schizophrenia: Toward a reformation for lack of an adequate response. J Exp Clin Med 4: 98–102.
45. Moncrieff J, (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersenstivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114: 3–13.
46. Nakata Y, Kanahara N, Kimura H. (2016) Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol 32: 169–173.
47. Oda Y, Kanahara N, Iyo M, (2015) Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: The pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci 16: 30144–30163.
48. Peluso MJ, Lewis SW, Barnes TRE. (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200: 387–392.
49. Peuskens J, (1999) The evolving definition of treatment resistance. J Clin Psychiatry 60(Suppl. 12): 4–8.
50. Quintero J, del Cura EB, López-lbor MI. (2011) The evolving concept of treatment-resistant schizophrenia. Actas Esp Psiquiatr 39: 236–250.
51. Rajkumar RP, (2014) Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder. Case Report Psychiatry 2014: 215732.
52. Robinson DG, Woerner MG, Alvir JMJ. (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156: 544–549.
53. Samaha AN, Seeman P, Stewart J. (2007) “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27: 2979–2986.
54. Seeman P, (2002) Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47: 27–38.
55. Seeman P, (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Therapeutics 17: 118–132.
56. Seeman P, Chau-Wong M, Tedesco J. (1975) Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad USA 72: 4376–4380.
57. Seeman P, Lee T, Chau-Wong M. (1976) Antipsychotic drug dose and neuroleptic/dopamine receptors. Nature 261: 717–719.
58. Seeman P, Tallerico T, (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156: 876–884.
59. Silvestri S, Seeman MV, Negrete JC. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl) 152: 174–180.
60. Small JG, Milstein V, Marhenke JD. (1987) Treatment outcome with clozapine in tardive syskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 48: 263–267.
61. Stroup TS, Gerhard T, Crystal S. (2016) Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 173: 166–173.
62. Suzuki T, Kanahara N, Yamanaka H. (2015) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Res 227: 278–282.
63. Tachibana M, Niitsu T, Watanabe M. (2016) Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis. Asian J Psychiatry 24: 28–32.
64. Tadokoro S, Okamura N, Sekine Y. (2011) Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 38: 1012–1020.
65. Takase M, Kanahara N, Oda Y. (2015) Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 29: 383–389.
66. Takeuchi H, Uchida H, Suzuki T. (2009) Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study. J Clin Psychopharmacol 29: 394–395.
67. Tandon R, Jibson MD, (2002) Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome. Ann Clin Psychiatry 14: 123–129.
68. Tandon R, Keshavan MS, Nasrallah HA, (2008) Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 102: 1–18.
69. Tenjin A, Miyamoto S, Ninomiya Y. (2013) Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 9: 587–594.
70. Valenstein M, Copeland LA, Blow FC. (2002) Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 40: 630–639.
71. Vasconcelos SM, Nascimento VS, Nogueira CR. (2003) Effects of haloperidol on rat behavior and density of dopaminergic D2-like receptors. Behav Processes 63: 45–52.
72. Ventura J, Thames AD, Wood RC. (2010) Disorganization and reality distortion in schizophrenia: A meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res 121: 1–14.
73. Yamada K, Shinkai T, Chen HI. (2014) Effect of COMT Val108/158Met genotype on risk for polydipsia in chronic patients with schizophrenia. Neuromolecular Med 16: 398–404.
74. Yamanaka H, Kanahara N, Suzuki T. (2016) Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis. Schizophr Res 170: 252–258.